Argenx SE (ARGX): A Promising Growth Stock to Buy on the Autoimmune Rheumatic Disease Opportunity

Argenx SE (NASDAQ:ARGX) is one of the most promising growth stocks to buy now. On June 4, H.C. Wainwright reiterated a Buy rating and a $940 price target on Argenx SE (NASDAQ:ARGX). The positive stance is in response to the company’s recent data showing VYVGART’s effectiveness across autoimmune rheumatic diseases.

Argenx SE (ARGX): A Promising Growth Stock to Buy on the Autoimmune Rheumatic Disease Opportunity

Pressmaster/Shutterstock.com

According to Luc Truyen, Chief Medical Officer at Argenx, the data underscore the rationale for targeting FcRn in autoimmune diseases and the potential to address unmet patient needs. The data support a favorable safety profile across multiple autoimmune rheumatic diseases. The company expects additional positive results from evaluating VYVGART in myositis and Sjogren’s disease next year.

Trial results from the ALKIVIA+ study indicate that VYVGART has the potential to deliver meaningful and sustained clinical benefit for patients with myositis. The candidate drug remains favorable across rheumatology indications. The US Food and Drug Administration has already approved a label expansion for VYVGART for the treatment of patients with generalized myasthenia gravis. The approval is based on data from the Phase 3 ADAPT SERON study.

Argenx SE (NASDAQ:ARGX) is a global immunology biotechnology company focused on developing antibody-based medicines for severe autoimmune diseases. Using proprietary research platforms like SIMPLE Antibody, they translate complex immunology breakthroughs into first-in-class therapies.

While we acknowledge the risk and potential of ARGX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ARGX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Billionaire Lee Ainslie’s 10 Stocks with Huge Upside Potential and 10 Deep Value Stocks to Invest In Now.

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1